Honasa Consumer has officially reported nearly 30% revenue growth in Q1 FY27, maintaining its projection of double-digit operating margins ahead of the board's formal financial results approval. The company disclosed this pre-results quarterly update for the quarter ended June 30, 2026, confirming its earlier projections of consolidated revenue growth around 30% year-on-year on an adjusted basis. On a reported basis, accounting for the change in revenue recognition policy by the Flipkart group affecting marketplace sellers like Honasa, the company expects YoY growth in the mid-twenties for Q1 FY27. The company has guided for a double-digit operating margin profile in Q1 FY27, with operating leverage from scale cited as a key contributor to sustained profitability.
Mamaearth, the company's flagship and largest brand, is expected to post high-teens revenue growth year-on-year, driven by improving consumer demand and an expanding offline distribution network. The company's portfolio of younger brands — which includes The Derma Co., Aqualogica, BBlunt, Dr. Sheth's, Staze, Lumineve and Reginald Men — is expected to grow at a faster clip, in the early forties percentage range. This optimistic outlook comes as the company continues its strategic expansion through recent acquisitions and subsidiary establishment. The company's offline channel remained a key growth engine, with both General Trade and Modern Trade expected to sustain strong momentum, aided by wider direct distribution reach and stronger in-store execution. The online channel is also expected to deliver healthy growth during the period, supporting the company's diversified distribution strategy across multiple channels.
Honasa Consumer has incorporated Honasa Health as a wholly owned subsidiary on July 7, 2026, marking a significant operational development following its strategic acquisition of Fluence Pharma. This incorporation represents the formal establishment of the subsidiary structure for the nutraceuticals business, building upon the 58% stake acquisition in Fluence Pharma at an enterprise value of approximately ₹135 crore that was completed earlier. The subsidiary incorporation allows for structured operations and governance framework for the nutraceuticals segment as Honasa Consumer continues to expand its presence in the broader beauty, wellness, and health categories.
Honasa Consumer, the parent company of Mamaearth, has acquired a 58% stake in nutraceuticals company Fluence Pharma at an enterprise value of approximately ₹135 crore, according to latest reports. The acquisition marks Honasa's entry into the nutraceuticals segment as it expands its presence in the broader beauty, wellness, and health categories. Founded in 2012 by Amit Bhusari and Dr Rajendra Singh Rajput, Fluence Pharma develops hair and skin health supplements marketed through dermatologists under brands including Hair Fact, Skin Fact and Pro Fact. The company has developed a patented Cyclical Nutrition Therapy (CNT) platform and works with a network of more than 3,000 dermatologists across India.
The stock was trading at ₹463.15 on the NSE on Thursday, down 0.95 per cent intraday, though shares have demonstrated strong long-term performance with a rally of over 63 per cent year-to-date and 53 per cent over the past year. The company's total market capitalisation stood at approximately ₹15,100 crore, with the stock currently trading at a trailing P/E of 76.10. Despite the positive corporate developments including the Fluence Pharma acquisition, strong Q1 performance, and recent subsidiary incorporation, the stock has shown mixed signals with recent intraday weakness. The company has indicated that a detailed information update will be issued following board approval of the full Q1 FY27 financial results.
